The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Merrimack Pharmaceuticals Inc

Nasdaq: MACK
Last

(U.S.) $13.42

Today's change-0.25 -1.83%
Updated April 24 4:00 PM -4GMT. Delayed by at least 15 minutes.
 

Merrimack Pharmaceuticals Inc

Nasdaq: MACK
Last

(U.S.) $13.42

Today's change-0.25 -1.83%
Updated April 24 4:00 PM -4GMT. Delayed by at least 15 minutes.

Sharp drop following new 52-week high

Merrimack Pharmaceuticals Inc closed sharply lower Friday, dropping (U.S.)$0.25 or 1.83% to (U.S.)$13.42 after setting a new 52-week high. Over the last five days, shares have gained 2.56% and are currently 2.54% off of the 52-week high. Shares have outperformed the S&P 500 by 165.12% during the last year.

Key company metrics

  • Open(U.S.) $13.66
  • Previous close(U.S.) $13.67
  • High(U.S.) $13.77
  • Low(U.S.) $13.42
  • Bid / Ask-- / --
  • YTD % change+18.76%
  • Volume756,371
  • Average volume (10-day)1,377,600
  • Average volume (1-month)1,378,644
  • Average volume (3-month)1,373,963
  • 52-week range(U.S.) $4.13 to (U.S.) $13.77
  • Beta--
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.80
Updated April 24 4:00 PM -4GMT. Delayed by at least 15 minutes.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2014Q3/2014Q2/2014Q1/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014
Revenue34282813
Total other revenue--------
Total revenue34282813
Gross profit--------
Total cost of revenue--------
Total operating expense39524237
Selling / general / administrative8886
Research & development31443430
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-5-24-14-24
Interest income (expense), net non-operating-5-5-5-5
Gain (loss) on sale of assets--------
Other--------
Income before tax-9-28-18-28
Income after tax-9-28-18-28
Income tax, total----00
Net income-10-28-18-28
Total adjustments to net income--------
Net income before extra. items-10-28-18-28
Minority interest0000
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-10-28-18-28
Inc. avail. to common incl. extra. items-10-28-18-28
Diluted net income-10-28-18-28
Dilution adjustment----00
Diluted weighted average shares106105104103
Diluted EPS excluding extraordinary itemsvalue per share-0.09-0.27-0.17-0.27
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share-0.09-0.27-0.17-0.27